Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

C4 Therapeutics (CCCC) Return on Sales (2019 - 2026)

C4 Therapeutics has reported Return on Sales over the past 8 years, most recently at 0.04% for Q1 2026.

  • For Q1 2026, Return on Sales changed 0.0% year-over-year to 0.04%; the TTM value through Mar 2026 reached 0.03%, changed 0.0%, while the annual FY2025 figure was 0.03%, 0.0% changed from the prior year.
  • Return on Sales for Q1 2026 was 0.04% at C4 Therapeutics, down from 0.02% in the prior quarter.
  • Over five years, Return on Sales peaked at 0.01% in Q2 2024 and troughed at 0.13% in Q2 2023.
  • A 5-year average of 0.06% and a median of 0.04% in 2026 define the central range for Return on Sales.
  • Biggest five-year swings in Return on Sales: fell -12bps in 2022 and later grew 12bps in 2024.
  • Year by year, Return on Sales stood at 0.13% in 2022, then increased by 18bps to 0.11% in 2023, then soared by 37bps to 0.07% in 2024, then surged by 72bps to 0.02% in 2025, then crashed by -121bps to 0.04% in 2026.
  • Business Quant data shows Return on Sales for CCCC at 0.04% in Q1 2026, 0.02% in Q4 2025, and 0.03% in Q3 2025.